



Helps Injected Drugs Spread Faster
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DOI 10.1016/j.chembiol.2007.06.002Research in biology has often focused
on what goes on inside cells and ig-
nored the surrounding scaffolding.
However, studies during the past de-
cade show that this scaffolding, called
the extracellular matrix, plays a major
role in intercellular signaling, wound re-
pair, cell differentiation, and other vital
processes. Among the building blocks
of the extracellular matrix is a complex
sugar called hyaluronan, a viscous
substance that acts as a barrier to fluidtransmission in mice at the Rockefeller
University (then Institute) in New York,
Duran-Reynals found that an extract
derived from rabbit testes increased
the spread of dyes injected under the
skin. In 1940, the late Karl Meyer, a
pioneering glycobiologist at Columbia
University, termed the active ingredi-
ent ‘‘hyaluronidase.’’ In the late 90s,
Robert Stern, M.D., of the University
of California at San Francisco and his
team,which included Frost, developed‘‘Using rHuPH20, you could take many types of drugs
that are given intravenously and potentially convert them
to subcutaneous administration,’’ says Gregory Frost,
Ph.D., cofounder and chief scientific officer of Halozyme
Therapeutics.flow. This barrier is not invincible—
a naturally occurring enzyme called
hyaluronidase can break it down and
make the tissue more permeable.
Many organisms exploit this enzyme’s
remarkable ability. Bees, stonefish,
and other venomous creatures inject
it to help spread their toxins. Leeches
employ it while feeding to improve
blood flow. Some species of bacteria
might use the compound to help infil-
trate host tissues. ‘‘The enzyme effec-
tively works as a molecular machete,’’
says Gregory Frost, Ph.D., cofounder
and chief scientific officer of San
Diego-based Halozyme Therapeutics
(http://www.halozyme.com), which
manufactures a recombinant version
of this enzyme for use as a ‘‘spreading
agent’’ to help the dispersal and ab-
sorption of coinjected drugs.
The credit for identifying hyaluroni-
dases’s potential as a spreading agent
goes to the late Catalan biologist
Francisco Duran-Reynals. In 1928,
while studying mechanisms of viraltechniques to isolate human hyaluron-
idase from blood and urine, then went
on to sequence the isolated isozyme
polypeptides and the genes involved.
‘‘When we put the sequences into the
gene bank, out came not one but six
genes,’’ recalls Stern. ‘‘Wewere simply
amazed.’’ It turned out that vertebrates
have six or more hyaluronidase genes,
while some primitive organisms such
as the nematode C. elegans have just
one. Stern hypothesizes that the six
genes may have evolved from a single
one by a series of duplication events.
‘‘Sometime between that tiny worm
and us vertebrates, all those events
occurred,’’ he says.
Two of the six hyaluronidase en-
zymes, termed Hyal-1 and Hyal-2, act
inside cells to break down tissue hya-
luronan. Another one, PH20, swings
into action during fertilization to help
spermatozoa to drill through the hya-
luronan coat that protects egg cells.
The remaining hyaluronidase enzymes
remain uncharacterized. Of the threeChemistry & Biology 14, June 2007 ªthat are well understood, only PH20
works in a pH-neutral medium, and
has therefore found extensive use as
a general-purpose spreading agent.
For decades, slaughterhouse extracts
of bull and ram testes have been the
main source of the enzyme for medical
applications. However, these extracts
have many contaminants, and the
PH20s in them are quite different from
the human version. These consider-
ations led Frost and other scientists to
found Halozyme Therapeutics—now
a publicly traded company with 50
employees—in 1998 to bring a re-
combinant human version of the en-
zyme to market. Full-length PH20
has a sequence region that anchors it
to the cell membrane, reducing its mo-
bility and making it insoluble. In late
2002, scientists at Halozyme discov-
ered that deleting this region resulted
in an active, soluble enzyme that could
depolymerize hyaluronan under physi-
ological conditions. They named this
form of the enzyme rHuPH20 (for re-
combinant Human PH20).
Animal and biochemical studies
showed that the new recombinant
enzyme was as at least as effective,
and potentially safer, than bovine hyal-
uronidase. Like the bovine enzyme,
rHuPH20 increased dispersion of in-
jected substances. Its effects were
temporary; the hyaluronan in the skin
reconstituted itself within hours after
the enzyme was injected. While it
was active, rHuPH20 allowed latex
beads of up to 200 nanometers in
size to move freely through the extra-
cellular matrix, indicating that it could
help disperse even large biologics
such as gene therapy vectors (which
are about 35 nm in size). When added
to a concentrated protein preparation,
it allowed the mixture to be infused 20
times faster through the skin. In a later
postmarket clinical trial with 54 human
subjects, the recombinant protein2007 Elsevier Ltd All rights reserved 603
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Innovationshelped to quadruple the flow rate of
a hydration fluid infused under the
skin. ‘‘Using rHuPH20, you could take
many types of drugs that are given
intravenously and potentially convert
them to subcutaneous administra-
tion,’’ concludes Frost.
‘‘The data are clear and convincing
that the recombinant protein can allow
diffusion into skin very effectively,’’
agrees hyaluronan expert VincentHas-
call of theClevelandClinic inOhio, who
has no ties to Frost’s company. ‘‘I like
the idea that this is a process that
temporarily alters the matrix to allow
diffusion but then the matrix quickly
restores fairly normal function. That is
neat.’’ The recombinant protein’s close
similarity to the human enzyme would
make adverse immune reactions less
likely compared to animal-based
products, Hascall adds.
Encouraged by the preclinical study
findings with rHuPH20, Halozyme
signed an exclusive agreement in
August 2004 with Deerfield, IL, based
Baxter Healthcare Corporation to mar-
ket the enzyme as an adjuvant for en-
hanced delivery of injected drugs, con-
trast agents, and subcutaneous
hydration fluids. The Halozyme team
was confident of being able to get the
drug approved by the Food and Drug
Administration (FDA) without new clin-
ical trials. ‘‘Officials at Baxter were ini-
tially skeptical about that,’’ says Frost.
But Halozyme had an ace up its sleeve.
In seeking FDA approval for its new
drug, Halozyme could rely on the track
record of existing hyaluronidase prod-
ucts dating back to 1948, when the
agency first allowed Madison, NJ,
basedWyeth to market bovine testicu-
lar hyaluronidase as a spreading agent
under the brand name Wydase. An
FDA drug efficacy study implementa-
tion report published in 1970 endorsed
the enzyme’s effectiveness. Since
then, hyaluronidase has been widely
used and is generally regarded as
safe when used as intended. (Addi-
tionally, although the practice is not
encouraged by manufacturers, the en-
zyme also finds a number of ‘‘off-
label’’ uses: to break down scar tissue
after a failed back surgery, to treat
tears and hemorrhages in the eye,
and to remove excess hyaluronan
during skin surgery.) In March 2005,604 Chemistry & Biology 14, June 2007 ªwhen Halozyme filed a new drug appli-
cation (NDA) for a low-dose formula-
tion of rHuPH20 as a spreading agent,
it invoked Section 505(b)(2) of the Fed-
eral Food, Drug, and Cosmetic Act to
cite previously published safety and ef-
ficacy studies for Wydase to support
its claims. ‘‘We went from DNA to NDA
in 21months,’’ says Frost. ‘‘That is one
of the fastest times ever that anyone
hasdone that for a recombinant human
biologic.’’ The FDA accepted the appli-
cation in May 2005, and in December
of that year, only 9 months after Halo-
zyme’s filing, approved the new drug.
Major deals quickly followed. Last
December, Halozyme entered into
a collaboration agreement with Basel,
Switzerland, based Roche, which
makes several leading biologics in-
cluding the antiviral drug Pegasys and
the monoclonal antibody-based can-
cer drugs Avastin and Herceptin. The
agreement gave Roche an exclusive
worldwide license to develop and
market exclusive coformulations of
rHuPH20with 13of its owndrugs. In re-
turn, Roche agreed to pay $20 million
up front, invest $11 million in equity,
and pay $111 million in milestones for
its first three targets. It would give a fur-
ther $47 million for each of the ten
remaining targets in up-front and mile-
stone payments. In total, the Roche
deal could be worth more than $600
million, says Jonathan Lim,M.D., Halo-
zyme’spresident andCEO. InFebruary
this year, the Baxter deal was ex-
panded to allow the company to use
rHuPH20 in combination with certain
proprietary and nonproprietary small
molecule drugs. Baxter agreed to pay
Halozyme $10 million up front, invest
$20 million in equity, and make other
milestone payments. The deal could
be worth nearly $65 million, says Lim.
Halozyme seems to be in the
enviable position of having no direct
competition. The company’s En-
hanze technology—hyaluronidase-
aided subcutaneous injection of large
drug volumes—compares favorably
with other existing alternatives to IV
delivery, says Frost. It is potentially
less invasive than intraosseous infu-
sion, in which the needle is injected
directly into the bone marrow and
can deliver larger volumes than trans-
dermal and pulmonary methods. Only2007 Elsevier Ltd All rights reservedoral delivery could in theory deliver
comparable drug volumes, provided
the drug could be reformulated to
make it easy to absorb through the
digestive system. ‘‘People are working
on this, but it is not an immediate pros-
pect,’’ says Frost.
As a spreading agent, rHuPH20
could become the preferred choice in
many applications, thanks to its low
risk of provoking an immune response.
In some niche markets, however,
existing animal-based products might
be safe enough. For instance, Vitrase,
a sheep-derived hyaluronidase formu-
lation made by Irvine, CA, based ISTA
Pharmaceuticals, is widely used in
ophthalmic surgery. Adverse immune
reactions rarely occur in this setting,
according to Bruce Aird, a scientist at
ISTA. ‘‘The eye is kind of a closed bio-
logical system with respect to the
body,’’ he says. ‘‘A lot of the benefits
associated with a humanized product
are irrelevant there.’’ Companies that
market animal-derived hyaluronidase,
however, may have to deal with limited
supplies as well as other safety con-
cerns relating to the use of animal
extracts. History favors Halozyme’s
model of switching from an animal-
derived product to a recombinant hu-
man version, Frost says. ‘‘People no
longer use bovine or porcine insulin,
nor do they extract human growth
hormone from cadavers.’’
The market seems to reflect his
optimism. During the past year, after
the Roche and Baxter deals were
announced, Halozyme’s stock rose
from less than $2 per share to about
$10.50, lifting the company’s market
capitalization to more than $750
million. This trend could continue if
the company gets FDA approval for
other products it is developing, which
include hyaluronidase-based drugs
for inflammation, cancer, and neurol-
ogy. ‘‘Ourgoal is tobecome the leading
provider of extracellular matrix-based
therapeutics,’’ says Frost. With a cash
reserve of $100 million, new products
in the pipeline, and nearly a dozen pat-
ents under its belt, Halozyme is well
poised to achieve that goal.
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